Other News To Note
Thursday, June 30, 2011
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said its therapeutic DNA vaccine INO-5150 for prostate cancer-generated T-cell immune responses in monkeys. The company plans to start a Phase I trial in 2012.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.